Skip Nav Destination
Issues
15 March 2007
-
Cover Image
Cover Image
U87MG glioma cells expressing the de2-7 EGFR (or EGFRvIII) were transiently transfected with the lysosomal marker lgp-120 tagged with GFP (green staining). After transfection, cells were incubated with mAb 806-cy3 at 4°C (red staining), before induction of internalization by incubating at 37°C for 0 (top left), 30 (top right), 60 (bottom left) and 120 (bottom right) minutes. Colocalization of mAb 806-Cy3 and lgp-120-GFP in the lysosomes can be clearly observed at 60 and 120 minutes (yellow staining). For further details, please see Johns et al. on page 1911 in this issue.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Editorial
The Biology Behind
CCR Practice of Translational Oncology
Molecular Pathways
CCR Focus
Human Cancer Biology
Identification and Prognostic Significance of an Epithelial-Mesenchymal Transition Expression Profile in Human Bladder Tumors
Egbert Baumgart; Michael S. Cohen; Brasil Silva Neto; Micah A. Jacobs; Chad Wotkowicz; Kimberly M. Rieger-Christ; Andreia Biolo; Ron Zeheb; Massimo Loda; John A. Libertino; Ian C. Summerhayes
Distinct Mitotic Segregation Errors Mediate Chromosomal Instability in Aggressive Urothelial Cancers
Yuesheng Jin; Ylva Stewénius; David Lindgren; Attila Frigyesi; Olga Calcagnile; Tord Jonson; Anna Edqvist; Nina Larsson; Lena Maria Lundberg; Gunilla Chebil; Fredrik Liedberg; Sigurdur Gudjonsson; Wiking Månsson; Mattias Höglund; David Gisselsson
Global Expression Analysis of Cancer/Testis Genes in Uterine Cancers Reveals a High Incidence of BORIS Expression
John Ian Risinger; Gadisetti V.R. Chandramouli; G. Larry Maxwell; Mary Custer; Svetlana Pack; Dmitri Loukinov; Olga Aprelikova; Tracy Litzi; David S. Schrump; Susan K. Murphy; Andrew Berchuck; Victor Lobanenkov; J. Carl Barrett
Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage
Morgan Rouprêt; Vincent Hupertan; David R. Yates; James W.F. Catto; Ishtiaq Rehman; Mark Meuth; Sylvie Ricci; Roger Lacave; Géraldine Cancel-Tassin; Alexandre de la Taille; François Rozet; Xavier Cathelineau; Guy Vallancien; Freddie C. Hamdy; Olivier Cussenot
Imaging, Diagnosis, Prognosis
Survivin and B7-H1 Are Collaborative Predictors of Survival and Represent Potential Therapeutic Targets for Patients with Renal Cell Carcinoma
Amy E. Krambeck; Haidong Dong; R. Houston Thompson; Susan M. Kuntz; Christine M. Lohse; Bradley C. Leibovich; Michael L. Blute; Thomas J. Sebo; John C. Cheville; Alexander S. Parker; Eugene D. Kwon
Cancer Therapy: Clinical
Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers
Ramesh K. Ramanathan; Merrill J. Egorin; Julie L. Eiseman; Suresh Ramalingam; David Friedland; Sanjiv S. Agarwala; S. Percy Ivy; Douglas M. Potter; Gurkamal Chatta; Eleanor G. Zuhowski; Ronald G. Stoller; Cynthia Naret; Jianxia Guo; Chandra P. Belani
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer
David B. Solit; S. Percy Ivy; Catherine Kopil; Rachel Sikorski; Michael J. Morris; Susan F. Slovin; W. Kevin Kelly; Anthony DeLaCruz; Tracy Curley; Glenn Heller; Steven Larson; Lawrence Schwartz; Merrill J. Egorin; Neal Rosen; Howard I. Scher
Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study
Rochelle Bagatell; Lia Gore; Merrill J. Egorin; Richard Ho; Glenn Heller; Nichole Boucher; Eleanor G. Zuhowski; James A. Whitlock; Stephen P. Hunger; Aru Narendran; Howard M. Katzenstein; Robert J. Arceci; Jessica Boklan; Cynthia E. Herzog; Luke Whitesell; S. Percy Ivy; Tanya M. Trippett
A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study
Brenda J. Weigel; Susan M. Blaney; Joel M. Reid; Stephanie L. Safgren; Rochelle Bagatell; John Kersey; Joseph P. Neglia; S. Percy Ivy; Ashish M. Ingle; Luke Whitesell; Richard J. Gilbertson; Mark Krailo; Matthew Ames; Peter C. Adamson
Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma
Bernard Escudier; Nathalie Lassau; Eric Angevin; Jean Charles Soria; Linda Chami; Michele Lamuraglia; Eric Zafarana; Veronique Landreau; Brian Schwartz; Eric Brendel; Jean-Pierre Armand; Caroline Robert
A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer
Denis C. Talbot; Joachim von Pawel; Emma Cattell; S. Murray Yule; Claire Johnston; Anthe S. Zandvliet; Alwin D.R. Huitema; Chris J. Norbury; Paul Ellis; Leon Bosquee; Martin Reck
Cancer Therapy: Preclinical
Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer
Jordan S. Fridman; Eian Caulder; Michael Hansbury; Xiangdong Liu; Genjie Yang; Qian Wang; Yvonne Lo; Bin-Bing Zhou; Maxwell Pan; Sufi M. Thomas; Jennifer R. Grandis; Jincong Zhuo; Wenqing Yao; Robert C. Newton; Steven M. Friedman; Peggy A. Scherle; Kris Vaddi
The Efficacy of Epidermal Growth Factor Receptor–Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization
Terrance G. Johns; Rushika M. Perera; Sonja C. Vernes; Angela A. Vitali; Diana X. Cao; Webster K. Cavenee; Andrew M. Scott; Frank B. Furnari
Advertisement